Company news

Botanix Pharmaceuticals Limited news in 2023

Botanix Pharmaceuticals Limited's news releases, calls and decks from 2023, newest first.

View company

Botanix Resubmission of NDA for Sofdra Completed

December 20, 2023

Successful Completion of Human Factors Study

December 13, 2023

FDA Confirms Approach to Sofdra NDA Resubmission

December 3, 2023

Successful Completion of $13.5m Institutional Placement

November 30, 2023

Botanix Placement Secures $13.5M to Fund Sofdra Launch Prep

November 26, 2023

Investor Presentation and Investor Meetings

October 30, 2023

September 2023 Quarterly Activities Report and Appendix 4C

October 30, 2023

Presentation- FDA Letter Requires Patient Instruction Update

September 25, 2023

FDA Letter Requires Patient Instruction Update

September 25, 2023

Response to ASX Price and Volume Query

September 20, 2023

Appendix 4E Preliminary Final Report

August 31, 2023

Appointment of Dr Howie McKibbon as CEO

August 24, 2023

June 2023 Quarterly Activities Report and Appendix 4C

July 30, 2023

Botanix Closes Capital Raising and Royalty Milestone Buyout

July 26, 2023

Botanix Capital Raising to Extinguish Milestone & Royalty

July 21, 2023

Botanix Pharmaceuticals: The West Australian | Botanix Pharmaceuticals secures $12.5m via an institutional placement

July 20, 2023

New Territory Licensed for Sofpironium Bromide with Kaken

June 5, 2023

March 2023 Quarterly Activities Report and Appendix 4C

April 28, 2023

Botanix successfully completes A$10m Placement

April 12, 2023

Botanix Raises A$10 million via Institutional Placement

April 5, 2023

FDA Mid-Cycle Review Meeting Successfully Completed

April 2, 2023

Half Yearly Report and Accounts

February 28, 2023

Press Article Correction

February 14, 2023

Appendix 4C - Quarterly

January 30, 2023

Decks in 2023